Esketamine Is Superior to Quetiapine for Remission of Treatment-Resistant Depression
Am Fam Physician. 2024 Feb;109(2):Online.NO ABSTRACTPMID:38393811 (Source: American Family Physician)
Source: American Family Physician - February 23, 2024 Category: Primary Care Authors: Mark H Ebell Source Type: research

Esketamine Is Superior to Quetiapine for Remission of Treatment-Resistant Depression
Am Fam Physician. 2024 Feb;109(2):Online.NO ABSTRACTPMID:38393811 (Source: American Family Physician)
Source: American Family Physician - February 23, 2024 Category: Primary Care Authors: Mark H Ebell Source Type: research

Esketamine Is Superior to Quetiapine for Remission of Treatment-Resistant Depression
Am Fam Physician. 2024 Feb;109(2):Online.NO ABSTRACTPMID:38393811 (Source: American Family Physician)
Source: American Family Physician - February 23, 2024 Category: Primary Care Authors: Mark H Ebell Source Type: research

Esketamine Is Superior to Quetiapine for Remission of Treatment-Resistant Depression
Am Fam Physician. 2024 Feb;109(2):Online.NO ABSTRACTPMID:38393811 (Source: American Family Physician)
Source: American Family Physician - February 23, 2024 Category: Primary Care Authors: Mark H Ebell Source Type: research

Esketamine Is Superior to Quetiapine for Remission of Treatment-Resistant Depression
Am Fam Physician. 2024 Feb;109(2):Online.NO ABSTRACTPMID:38393811 (Source: American Family Physician)
Source: American Family Physician - February 23, 2024 Category: Primary Care Authors: Mark H Ebell Source Type: research

Dose-dependent effect of lamotrigine on quetiapine serum concentration in patients using instant release tablets
ConclusionThe effect of lamotrigine in reducing quetiapine concentration is only significant for patients using quetiapine IR tablets who are treated with lamotrigine doses  >  200 mg/day. Because of high variability in the interaction effect, TDM of quetiapine should be recommended during co-prescription of high-dose lamotrigine. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - February 23, 2024 Category: Drugs & Pharmacology Source Type: research

Is Quetiapine the Best Option for Patients With Antipsychotic-Induced Disorders of Extrinsic Ocular Motricity?
Prim Care Companion CNS Disord. 2024 Feb 13;26(1):23cr03606. doi: 10.4088/PCC.23cr03606.NO ABSTRACTPMID:38382070 | DOI:10.4088/PCC.23cr03606 (Source: Primary Care)
Source: Primary Care - February 21, 2024 Category: Primary Care Authors: Marco De Pieri Source Type: research

Is Quetiapine the Best Option for Patients With Antipsychotic-Induced Disorders of Extrinsic Ocular Motricity?
Prim Care Companion CNS Disord. 2024 Feb 13;26(1):23cr03606. doi: 10.4088/PCC.23cr03606.NO ABSTRACTPMID:38382070 | DOI:10.4088/PCC.23cr03606 (Source: The Primary Care Companion for CNS Disorders)
Source: The Primary Care Companion for CNS Disorders - February 21, 2024 Category: Primary Care Authors: Marco De Pieri Source Type: research

Is Quetiapine the Best Option for Patients With Antipsychotic-Induced Disorders of Extrinsic Ocular Motricity?
Prim Care Companion CNS Disord. 2024 Feb 13;26(1):23cr03606. doi: 10.4088/PCC.23cr03606.NO ABSTRACTPMID:38382070 | DOI:10.4088/PCC.23cr03606 (Source: Primary Care)
Source: Primary Care - February 21, 2024 Category: Primary Care Authors: Marco De Pieri Source Type: research

Is Quetiapine the Best Option for Patients With Antipsychotic-Induced Disorders of Extrinsic Ocular Motricity?
Prim Care Companion CNS Disord. 2024 Feb 13;26(1):23cr03606. doi: 10.4088/PCC.23cr03606.NO ABSTRACTPMID:38382070 | DOI:10.4088/PCC.23cr03606 (Source: The Primary Care Companion for CNS Disorders)
Source: The Primary Care Companion for CNS Disorders - February 21, 2024 Category: Primary Care Authors: Marco De Pieri Source Type: research

Withdrawal syndrome after antipsychotics discontinuation: an analysis of the WHO database of spontaneous reports (Vigibase) between 2000 and 2022
ConclusionOur results suggest that there might be a risk difference for WDS between antipsychotics. Tiotixene, pimozide and quetiapine were associated with a higher risk of reporting a WDS whereas this risk was lower with chlorpromazine, clozapine and fluphenazine. We could not address the issue of withdrawal psychosis, withdrawal dyskinesia, rebound psychosis or supersensitivity psychosis due to the lack of specific WHO medDRA coded terms to identify potential cases. (Source: Psychopharmacology)
Source: Psychopharmacology - February 20, 2024 Category: Psychiatry Source Type: research

CMS Prescription Trends for Quetiapine are Increasing: Can This Be Secondary to Off-Label Use?
Quetiapine is an atypical antipsychotic that is FDA approved for the treatment of schizophrenia, acute mania in bipolar 1 disorder, bipolar depression, and as an adjunct in major depressive disorder (MDD). Likely due to quetiapine's broad action amongst neurotransmitter receptors, and favorable side effect profile compared to other antipsychotic medications, the use of quetiapine is widespread for a variety of off-label diagnoses. Here we present information on the trends of the prescription of quetiapine from the center for Medicare and Medicaid Services (CMS) database. (Source: The American Journal of Geriatric Psychiatry)
Source: The American Journal of Geriatric Psychiatry - February 18, 2024 Category: Geriatrics Authors: Dana Ferrara, Adam Fusick, Steven Gunther, Sean Smith Tags: Poster # EI29 Source Type: research

Navigating the Platelet Puzzle: Clozapine Treatment in Parkinson's Disease - The Dilemma of Continuation
Parkinson's disease is one of the most common neurodegenerative diseases, strongly affecting the well-being of patients and caregivers. Neuropsychiatric symptoms of Parkinson's disease include psychosis, dementia, depression, anxiety, REM sleep behavior disorder, and impulse control disorders. In patients with Parkinson's disease with distressing psychosis, pimavanserin, quetiapine, and clozapine can be used. Clozapine has fewer motor effects compared with other antipsychotic agents, though there are many side effects to consider. (Source: The American Journal of Geriatric Psychiatry)
Source: The American Journal of Geriatric Psychiatry - February 18, 2024 Category: Geriatrics Authors: Arielle Silbersweig, Cristina M. Pritchett, Claudio S. Bondulich, Adriana P. Hermida Tags: Poster # EI39 Source Type: research